Core Viewpoint - Regional Health Properties, Inc. has announced a Stock Repurchase Plan to buy back up to 500,000 shares of its Series B Preferred Stock, which will be overseen by a Special Committee of the Board of Directors [1][3]. Summary by Sections Stock Repurchase Plan - The Company is authorized to purchase shares of Series B Preferred Stock through various methods including open-market transactions and block trades, in accordance with relevant securities regulations [2]. - The repurchase program does not obligate the Company to buy back any shares during any specific period and will be funded by cash on hand [3]. - The program is expected to continue indefinitely until the maximum number of shares is repurchased or the program is modified, suspended, or terminated by the Board [3]. Company Overview - Regional Health Properties, Inc. is a self-managed healthcare real estate investment company based in Atlanta, Georgia, primarily investing in real estate for senior living and long-term care [4].

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from a previous plan [1][2]. Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1]. - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1]. - The repurchase may occur through open market transactions or other means, with the plan set to expire on March 31, 2026, and can be suspended or discontinued at any time [3]. Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2]. Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4]. - The company has out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [4]. - AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5].

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from the previous plan [1][2] Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1] - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1] - The new plan will expire on March 31, 2026, and the timing and number of shares repurchased will depend on market conditions and other factors [3] Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4] - The company plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5]

Core Insights - Block, Inc. is hosting its 2025 Investor Day on November 19, 2025, at 9:00 a.m. Pacific Time in San Francisco [1] - The company will present full-year 2026 financial guidance and a three-year financial outlook during the event [1] - Block, Inc. is increasing its stock repurchase program by $5 billion as part of its broader capital allocation strategy [1] Financial Guidance - Full-year 2026 financial guidance will be provided during the Investor Day [1] - A three-year financial outlook will also be discussed [1] Capital Allocation Strategy - The company is increasing its stock repurchase program by $5 billion [1]

Core Viewpoint - Bank7 Corp. will release its financial results for Q3 2025 on October 15, 2025, and will hold a conference call to discuss these results with investors [1]. Company Overview - Bank7 Corp. is a bank holding company based in Oklahoma City, operating through its subsidiary Bank7, with twelve locations across Oklahoma, the Dallas/Fort Worth area, and Kansas [3]. - The company focuses on serving business owners and entrepreneurs by providing fast and well-designed loan and deposit products [3]. - Bank7 Corp. aims for organic growth by selectively opening new branches in target markets and pursuing strategic acquisitions [3]. Financial Announcements - A conference call will take place on October 15, 2025, at 9:00 a.m. CST, where investors can participate by dialing 1-888-348-6421 or accessing it online [1]. - An archive of the webcast will be available for one year after the call for those unable to attend live [2].

Core Viewpoint - RBB Bancorp has authorized a stock repurchase plan for up to $18 million of its outstanding common stock, effective through June 30, 2026, indicating a commitment to returning value to shareholders [1][2]. Company Overview - RBB Bancorp is a community-based financial holding company headquartered in Los Angeles, California, with total assets of $4.0 billion as of March 31, 2025 [3]. - The company's subsidiary, Royal Business Bank, operates 24 full-service branches across six states, primarily serving Asian-centric communities [3]. - The bank offers a variety of services including consumer and business banking, commercial loans, and wealth management [3]. Stock Repurchase Plan Details - The repurchase plan allows for shares to be bought in open market or private transactions, and can be suspended or modified based on various factors such as market conditions and liquidity [2]. - The plan does not obligate the company to repurchase a specific number of shares, providing flexibility in execution [2].

Core Points - Mission Bancorp has extended its stock repurchase plan and approved a 5.00% stock dividend, reflecting the company's strong performance amid uncertainty [1][2] - The stock repurchase plan allows for a maximum of $3.0 million in common stock to be repurchased, with an extension through October 23, 2025 [2] - The 5.00% stock dividend will be issued on June 2, 2025, to shareholders of record as of May 19, 2025 [3] Company Overview - Mission Bancorp has $1.9 billion in assets and operates four wholly owned subsidiaries, including Mission Bank [4] - The company serves various regions in California through eight Business Banking Centers [4]

Core Viewpoint - OraSure Technologies, Inc. has authorized a stock repurchase program of up to $40 million over the next twenty-four months, to be funded from cash on hand [1][2]. Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions, aiming to improve access, quality, and value of healthcare through innovative testing and sample management [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., develops, manufactures, and distributes rapid diagnostic tests and sample collection devices globally [3]. Stock Repurchase Program - The stock repurchase may be executed through various methods in compliance with applicable laws, with the timing and amount determined at the management's discretion [2]. - The repurchase program can be modified, suspended, or discontinued at any time without prior notice [2].